Pyronaridine/artesunate included in the list of WHO prequalified medicines | MMV

Initially, Pyramax will be registered in areas of low malaria transmission where there is reported artemisinin resistance and diminished efficacy of other ACTs. Until further data after retreatment is obtained, Pyramax use will be restricted to a single course of treatment. Meantime, MMV and Shin Poong are conducting additional studies to investigate the safety of Pyramax after repeat-administration.

The Pyramax dossier has been submitted for regulatory approval to Myanmar and Vietnam, and is currently being processed. It is also being prepared for submission to Cambodia and Thailand.

Once approved in these countries, this ACT will serve as an important public health tool in WHO’s artemisinin resistance containment strategy. The prequalification of Pyramax is a key step towards the achievement of that goal.

via Pyronaridine/artesunate included in the list of WHO prequalified medicines | MMV.

Advertisements


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s